Product Revenue Reserves and Allowances

12 Months Ended

Dec. 31, 2022

Product Revenue Reserves and Allowances

Product Revenue Reserves and Allowances

D.Product Revenue Reserves and Allowances

In November 2022, the FDA granted accelerated approval for ELAHERE for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The Company recorded net product revenue of $2.6 million from U.S. sales of ELAHERE through December 31, 2022.

The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2022 and 2021 (in thousands):

	December 31,		December 31,
	2022		2021
Beginning balance at January 1	$	—	$	—
Provision related to sales in the current period		313		—
Credits and payments made		—		—
Ending balance at December 31	$	313	$	—